Skip to main content
placeholder image

Medicinal chemistry, pharmacology, and therapeutic potential of a-conotoxins antagonizing the a9a10 nicotinic acetylcholine receptor

Journal Article


Abstract


  • α-Conotoxins are disulfide-rich and well-structured peptides, most of which can block nicotinic acetylcholine receptors (nAChRs) with exquisite selectivity and potency. There are various nAChR subtypes, of which the α9α10 nAChR functions as a heteromeric ionotropic receptor in the mammalian cochlea and mediates postsynaptic transmission from the medial olivocochlear. The α9α10 nAChR subtype has also been proposed as a target for the treatment of neuropathic pain and the suppression of breast cancer cell proliferation. Therefore, α-conotoxins targeting the α9α10 nAChR are potentially useful in the development of specific therapeutic drugs and pharmacological tools. Despite dissimilarities in their amino acid sequence and structures, these conopeptides are potent antagonists of the α9α10 nAChR subtype. Consequently, the activity and stability of these peptides have been subjected to chemical modifications. The resulting synthetic analogues have not only functioned as molecular probes to explore ligand binding sites of the α9α10 nAChR, but also have the potential to become candidates for drug development. From the perspectives of medicinal chemistry and pharmacology, we highlight the structure and function of the α9α10 nAChR and review studies of α-conotoxins targeting it, including their three-dimensional structures, structure optimization strategies, and binding modes at the α9α10 nAChR, as well as their therapeutic potential.

Publication Date


  • 2021

Citation


  • Li, X., Tae, H. S., Chu, Y., Jiang, T., Adams, D. J., & Yu, R. (2021). Medicinal chemistry, pharmacology, and therapeutic potential of a-conotoxins antagonizing the a9a10 nicotinic acetylcholine receptor. Pharmacology and Therapeutics, 222. doi:10.1016/j.pharmthera.2020.107792

Scopus Eid


  • 2-s2.0-85098603022

Volume


  • 222

Abstract


  • α-Conotoxins are disulfide-rich and well-structured peptides, most of which can block nicotinic acetylcholine receptors (nAChRs) with exquisite selectivity and potency. There are various nAChR subtypes, of which the α9α10 nAChR functions as a heteromeric ionotropic receptor in the mammalian cochlea and mediates postsynaptic transmission from the medial olivocochlear. The α9α10 nAChR subtype has also been proposed as a target for the treatment of neuropathic pain and the suppression of breast cancer cell proliferation. Therefore, α-conotoxins targeting the α9α10 nAChR are potentially useful in the development of specific therapeutic drugs and pharmacological tools. Despite dissimilarities in their amino acid sequence and structures, these conopeptides are potent antagonists of the α9α10 nAChR subtype. Consequently, the activity and stability of these peptides have been subjected to chemical modifications. The resulting synthetic analogues have not only functioned as molecular probes to explore ligand binding sites of the α9α10 nAChR, but also have the potential to become candidates for drug development. From the perspectives of medicinal chemistry and pharmacology, we highlight the structure and function of the α9α10 nAChR and review studies of α-conotoxins targeting it, including their three-dimensional structures, structure optimization strategies, and binding modes at the α9α10 nAChR, as well as their therapeutic potential.

Publication Date


  • 2021

Citation


  • Li, X., Tae, H. S., Chu, Y., Jiang, T., Adams, D. J., & Yu, R. (2021). Medicinal chemistry, pharmacology, and therapeutic potential of a-conotoxins antagonizing the a9a10 nicotinic acetylcholine receptor. Pharmacology and Therapeutics, 222. doi:10.1016/j.pharmthera.2020.107792

Scopus Eid


  • 2-s2.0-85098603022

Volume


  • 222